-
1
-
-
20144373530
-
Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects
-
15685244
-
Dearnaley DP, Hall E, Lawrence D, Huddart RA, Eeles R, et al. (2005) Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 92: 488-498. PubMed: 15685244.
-
(2005)
Br J Cancer
, vol.92
, pp. 488-498
-
-
Dearnaley, D.P.1
Hall, E.2
Lawrence, D.3
Huddart, R.A.4
Eeles, R.5
-
2
-
-
33748096108
-
Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer
-
doi: 10.1016/j.juro.2006.06.002
-
Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, et al. (2006) Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176: 1415-1419. doi:10.1016/j.juro.2006.06.002. PubMed: 16952647.
-
(2006)
J Urol
, vol.176
, pp. 1415-1419
-
-
Zelefsky, M.J.1
Chan, H.2
Hunt, M.3
Yamada, Y.4
Shippy, A.M.5
-
3
-
-
53049089057
-
Postradiation sensitization of the histone deacetylase inhibitor valproic acid
-
doi: 10.1158/1078-0432.CCR-08-0643
-
Chinnaiyan P, Cerna D, Burgan WE, Beam K, Williams ES, et al. (2008) Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clin Cancer Res 14: 5410-5415. doi:10.1158/1078-0432.CCR-08-0643. PubMed: 18765532.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 5410-5415
-
-
Chinnaiyan, P.1
Cerna, D.2
Burgan, W.E.3
Beam, K.4
Williams, E.S.5
-
4
-
-
84874410182
-
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
-
23459471
-
Ververis K, Hiong A, Karagiannis TC, Licciardi PV, (2013) Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics 7: 47-60. PubMed: 23459471.
-
(2013)
Biologics
, vol.7
, pp. 47-60
-
-
Ververis, K.1
Hiong, A.2
Karagiannis, T.C.3
Licciardi, P.V.4
-
5
-
-
4143087257
-
Histone deacetylase inhibition and estrogen signalling in human breast cancer cells
-
doi: 10.1016/j.bcp.2004.04.031
-
Margueron R, Duong V, Castet A, Cavaillès V, (2004) Histone deacetylase inhibition and estrogen signalling in human breast cancer cells. Biochem Pharmacol 68: 1239-1246. doi:10.1016/j.bcp.2004.04.031. PubMed: 15313422.
-
(2004)
Biochem Pharmacol
, vol.68
, pp. 1239-1246
-
-
Margueron, R.1
Duong, V.2
Castet, A.3
Cavaillès, V.4
-
6
-
-
67349285731
-
Enhancing the apoptotic and therapeutic effects of HDAC inhibitors
-
doi: 10.1016/j.canlet.2009.02.042
-
Frew AJ, Johnstone RW, Bolden JE, (2009) Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 280: 125-133. doi:10.1016/j.canlet.2009.02.042. PubMed: 19359091.
-
(2009)
Cancer Lett
, vol.280
, pp. 125-133
-
-
Frew, A.J.1
Johnstone, R.W.2
Bolden, J.E.3
-
7
-
-
69849110970
-
Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors
-
doi: 10.2217/fon.09.36
-
Prince HM, Bishton MJ, Johnstone RW, (2009) Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol 5: 601-612. doi:10.2217/fon.09.36. PubMed: 19519200.
-
(2009)
Future Oncol
, vol.5
, pp. 601-612
-
-
Prince, H.M.1
Bishton, M.J.2
Johnstone, R.W.3
-
8
-
-
31544464120
-
Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589
-
doi: 10.1158/1078-0432.CCR-05-1132
-
Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, et al. (2006) Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res 12: 634-642. doi:10.1158/1078-0432.CCR-05-1132. PubMed: 16428510.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 634-642
-
-
Qian, D.Z.1
Kato, Y.2
Shabbeer, S.3
Wei, Y.4
Verheul, H.M.5
-
9
-
-
77951884767
-
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer
-
doi: 10.1007/s00280-010-1289-x
-
Rathkopf D, Wong BY, Ross RW, Anand A, Tanaka E, et al. (2010) A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 66: 181-189. doi:10.1007/s00280-010-1289-x. PubMed: 20217089.
-
(2010)
Cancer Chemother Pharmacol
, vol.66
, pp. 181-189
-
-
Rathkopf, D.1
Wong, B.Y.2
Ross, R.W.3
Anand, A.4
Tanaka, E.5
-
10
-
-
78649632254
-
Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer
-
doi: 10.1016/j.canlet.2010.09.013
-
Wang L, Chen H, Liu FH, Madigan MC, Power CA, et al. (2011) Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer. Cancer Lett 300: 122-133. doi:10.1016/j.canlet.2010.09.013. PubMed: 21075513.
-
(2011)
Cancer Lett
, vol.300
, pp. 122-133
-
-
Wang, L.1
Chen, H.2
Liu, F.H.3
Madigan, M.C.4
Power, C.A.5
-
11
-
-
68149138779
-
Coexpression of invasive markers (uPA, CD44) and multiple drug resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression
-
doi: 10.1038/sj.bjc.6605185
-
Chen H, Hao J, Wang L, Li Y, (2009) Coexpression of invasive markers (uPA, CD44) and multiple drug resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression. Br J Cancer 101: 432-440. doi:10.1038/sj.bjc.6605185. PubMed: 19603017.
-
(2009)
Br J Cancer
, vol.101
, pp. 432-440
-
-
Chen, H.1
Hao, J.2
Wang, L.3
Li, Y.4
-
12
-
-
85047699075
-
In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen
-
doi: 10.1038/sj.pcan.4500543
-
Li Y, Tian Z, Rizvi SM, Bander NH, Allen BJ, (2002) In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. Prostate Cancer Prostatic Dis 5: 36-46. doi:10.1038/sj.pcan.4500543. PubMed: 15195129.
-
(2002)
Prostate Cancer Prostatic Dis
, vol.5
, pp. 36-46
-
-
Li, Y.1
Tian, Z.2
Rizvi, S.M.3
Bander, N.H.4
Allen, B.J.5
-
13
-
-
77957234813
-
Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression
-
doi: 10.1038/sj.bjc.6605839
-
Hao J, Chen H, Madigan MC, Cozzi PJ, Beretov J, et al. (2010) Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression. Br J Cancer 103: 1008-1018. doi:10.1038/sj.bjc.6605839. PubMed: 20736947.
-
(2010)
Br J Cancer
, vol.103
, pp. 1008-1018
-
-
Hao, J.1
Chen, H.2
Madigan, M.C.3
Cozzi, P.J.4
Beretov, J.5
-
14
-
-
79955625505
-
Retention of the in vitro radiosensitizing potential of gemcitabine under anoxic conditions, in p53 wild-type and p53-deficient non-small-cell lung carcinoma cells
-
doi: 10.1016/j.ijrobp.2010.12.051
-
Wouters A, Pauwels B, Lambrechts HA, Pattyn GG, Ides J, et al. (2011) Retention of the in vitro radiosensitizing potential of gemcitabine under anoxic conditions, in p53 wild-type and p53-deficient non-small-cell lung carcinoma cells. Int J Radiat Oncol Biol Phys 80: 558-566. doi:10.1016/j.ijrobp.2010.12.051. PubMed: 21377279.
-
(2011)
Int J Radiat Oncol Biol Phys
, vol.80
, pp. 558-566
-
-
Wouters, A.1
Pauwels, B.2
Lambrechts, H.A.3
Pattyn, G.G.4
Ides, J.5
-
15
-
-
33748360764
-
Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci
-
doi: 10.1158/1535-7163.MCT-06-0022
-
Munshi A, Tanaka T, Hobbs ML, Tucker SL, Richon VM, et al. (2006) Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther 5: 1967-1974. doi:10.1158/1535-7163.MCT-06-0022. PubMed: 16928817.
-
(2006)
Mol Cancer Ther
, vol.5
, pp. 1967-1974
-
-
Munshi, A.1
Tanaka, T.2
Hobbs, M.L.3
Tucker, S.L.4
Richon, V.M.5
-
16
-
-
0142186650
-
How low is the α/β ratio for prostate cancer?
-
doi: 10.1016/S0360-3016(03)01455-X
-
Kal HB, Van Gellekom MP, (2003) How low is the α/β ratio for prostate cancer? Int J Radiat Oncol Biol Phys 57: 1116-1121. doi:10.1016/S0360-3016(03)01455-X. PubMed: 14575844.
-
(2003)
Int J Radiat Oncol Biol Phys
, vol.57
, pp. 1116-1121
-
-
Kal, H.B.1
Van Gellekom, M.P.2
-
17
-
-
3042661957
-
Role of cell cycle in mediating sensitivity to radiotherapy
-
doi: 10.1016/j.ijrobp.2004.03.005
-
Pawlik TM, Keyomarsi K, (2004) Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 59: 928-942. doi:10.1016/j.ijrobp.2004.03.005. PubMed: 15234026.
-
(2004)
Int J Radiat Oncol Biol Phys
, vol.59
, pp. 928-942
-
-
Pawlik, T.M.1
Keyomarsi, K.2
-
18
-
-
79954488451
-
Low-dose valproic acid enhances radiosensitivity of prostate cancer through acetylated p53-dependent modulation of mitochondrial membrane potential and apoptosis
-
doi: 10.1158/1541-7786.MCR-10-0471
-
Chen X, Wong JY, Wong P, Radany EH, (2011) Low-dose valproic acid enhances radiosensitivity of prostate cancer through acetylated p53-dependent modulation of mitochondrial membrane potential and apoptosis. Mol Cancer Res 9: 448-461. doi:10.1158/1541-7786.MCR-10-0471. PubMed: 21303901.
-
(2011)
Mol Cancer Res
, vol.9
, pp. 448-461
-
-
Chen, X.1
Wong, J.Y.2
Wong, P.3
Radany, E.H.4
-
19
-
-
84864882225
-
Enhancement of radiosensitivity by a unique novel NF-κB inhibitor, DHMEQ, in prostate cancer
-
doi: 10.1038/bjc.2012.321
-
Kozakai N, Kikuchi E, Hasegawa M, Suzuki E, Ide H, et al. (2012) Enhancement of radiosensitivity by a unique novel NF-κB inhibitor, DHMEQ, in prostate cancer. Br J Cancer 107: 652-657. doi:10.1038/bjc.2012.321. PubMed: 22805327.
-
(2012)
Br J Cancer
, vol.107
, pp. 652-657
-
-
Kozakai, N.1
Kikuchi, E.2
Hasegawa, M.3
Suzuki, E.4
Ide, H.5
-
20
-
-
0035895622
-
Pathways governing G1/S transition and their response to DNA damage
-
doi: 10.1016/S0014-5793(01)02114-7
-
Bartek J, Lukas J, (2001) Pathways governing G1/S transition and their response to DNA damage. FEBS Lett; 490: 117-122. doi:10.1016/S0014-5793(01)02114-7. PubMed: 11223026.
-
(2001)
FEBS Lett
, vol.490
, pp. 117-122
-
-
Bartek, J.1
Lukas, J.2
-
21
-
-
0030827303
-
Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein
-
doi: 10.1101/gad.11.16.2090
-
Funk JO, Waga S, Harry JB, Espling E, Stillman B, et al. (1997) Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev 11: 2090-2100. doi:10.1101/gad.11.16.2090. PubMed: 9284048.
-
(1997)
Genes Dev
, vol.11
, pp. 2090-2100
-
-
Funk, J.O.1
Waga, S.2
Harry, J.B.3
Espling, E.4
Stillman, B.5
-
22
-
-
51649092237
-
P53, cyclin-dependent kinase and abnormal amplification of centrosomes
-
18472015
-
Fukasawa K, (2008) P53, cyclin-dependent kinase and abnormal amplification of centrosomes. Biochim Biophys Acta 1786: 15-23. PubMed: 18472015.
-
(2008)
Biochim Biophys Acta
, vol.1786
, pp. 15-23
-
-
Fukasawa, K.1
-
23
-
-
0036261707
-
Sensing and repairing DNA double-strand breaks
-
doi: 10.1093/carcin/23.5.687
-
Jackson SP, (2002) Sensing and repairing DNA double-strand breaks. Carcinogenesis 23: 687-696. doi:10.1093/carcin/23.5.687. PubMed: 12016139.
-
(2002)
Carcinogenesis
, vol.23
, pp. 687-696
-
-
Jackson, S.P.1
-
24
-
-
39449085063
-
DNA-damage repair; the good, the bad, and the ugly
-
doi: 10.1038/emboj.2008.15
-
Hakem R, (2008) DNA-damage repair; the good, the bad, and the ugly. EMBO J 27: 589-605. doi:10.1038/emboj.2008.15. PubMed: 18285820.
-
(2008)
EMBO J
, vol.27
, pp. 589-605
-
-
Hakem, R.1
-
25
-
-
34548564426
-
Attenuated DNA damage repair by trichostatin A through BRCA1 suppression
-
doi: 10.1667/RR0811.1
-
Zhang Y, Carr T, Dimtchev A, Zaer N, Dritschilo A, et al. (2007) Attenuated DNA damage repair by trichostatin A through BRCA1 suppression. Radiat Res 168: 115-124. doi:10.1667/RR0811.1. PubMed: 17722998.
-
(2007)
Radiat Res
, vol.168
, pp. 115-124
-
-
Zhang, Y.1
Carr, T.2
Dimtchev, A.3
Zaer, N.4
Dritschilo, A.5
-
26
-
-
84866550710
-
Understanding histone deacetylases in the cancer development and treatment: an epigenetic perspective of cancer chemotherapy
-
22462686
-
Ahmad M, Hamid A, Hussain A, Majeed R, Qurishi Y, et al. (2012) Understanding histone deacetylases in the cancer development and treatment: an epigenetic perspective of cancer chemotherapy. DNA Cell Biol Suppl 1: S62-S71. PubMed: 22462686.
-
(2012)
DNA Cell Biol Suppl
, vol.1
-
-
Ahmad, M.1
Hamid, A.2
Hussain, A.3
Majeed, R.4
Qurishi, Y.5
-
27
-
-
43249120953
-
Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis
-
doi: 10.1007/978-1-4020-6554-5_13
-
Shankar S, Srivastava RK, (2008) Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. Adv Exp Med Biol 615: 261-298. doi:10.1007/978-1-4020-6554-5_13. PubMed: 18437899.
-
(2008)
Adv Exp Med Biol
, vol.615
, pp. 261-298
-
-
Shankar, S.1
Srivastava, R.K.2
-
28
-
-
79955678223
-
Developing histone deacetylase inhibitors as anti-cancer therapeutics
-
doi: 10.2174/092986711795471284
-
Venugopal B, Evans TR, (2011) Developing histone deacetylase inhibitors as anti-cancer therapeutics. Curr Med Chem 18: 1658-1671. doi:10.2174/092986711795471284. PubMed: 21428881.
-
(2011)
Curr Med Chem
, vol.18
, pp. 1658-1671
-
-
Venugopal, B.1
Evans, T.R.2
-
29
-
-
84875839227
-
The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers
-
doi: 10.1111/j.1464-410X.2012.11647.x
-
Sharma NL, Groselj B, Hamdy FC, Kiltie AE, (2013) The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers. BJU Int 111(4):: 537-542. doi:10.1111/j.1464-410X.2012.11647.x. PubMed: 23551441.
-
(2013)
BJU Int
, vol.111
, pp. 537-542
-
-
Sharma, N.L.1
Groselj, B.2
Hamdy, F.C.3
Kiltie, A.E.4
-
30
-
-
84875223519
-
Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair
-
doi: 10.1038/bjc.2013.21
-
Groselj B, Sharma NL, Hamdy FC, Kerr M, Kiltie AE, (2013) Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair. Br J Cancer 108(4):: 748-754. doi:10.1038/bjc.2013.21. PubMed: 23361058.
-
(2013)
Br J Cancer
, vol.108
, pp. 748-754
-
-
Groselj, B.1
Sharma, N.L.2
Hamdy, F.C.3
Kerr, M.4
Kiltie, A.E.5
-
31
-
-
84873823667
-
Epigenetics and persistent memory: implications for reconsolidation and silent extinction beyond the zero
-
doi: 10.1038/nn.3302
-
Lattal KM, Wood MA, (2013) Epigenetics and persistent memory: implications for reconsolidation and silent extinction beyond the zero. Nat Neurosci 16: 124-129. doi:10.1038/nn.3302. PubMed: 23354385.
-
(2013)
Nat Neurosci
, vol.16
, pp. 124-129
-
-
Lattal, K.M.1
Wood, M.A.2
-
32
-
-
0035142893
-
Chromosome regions enriched in hyperacetylated histone H4 are preferred sites for endonuclease- and radiation-induced breakpoints
-
doi: 10.1023/A:1026747801728
-
Martínez-López W, Folle GA, Obe G, Jeppesen P, (2001) Chromosome regions enriched in hyperacetylated histone H4 are preferred sites for endonuclease- and radiation-induced breakpoints. Chromosome Res 9: 69-75. doi:10.1023/A:1026747801728. PubMed: 11272794.
-
(2001)
Chromosome Res
, vol.9
, pp. 69-75
-
-
Martínez-López, W.1
Folle, G.A.2
Obe, G.3
Jeppesen, P.4
-
33
-
-
4344688693
-
Histone deacetylase inhibitors
-
doi: 10.1016/S0065-230X(04)91004-4
-
Marks PA, Richon VM, Miller T, Kelly WK, (2004) Histone deacetylase inhibitors. Adv Cancer Res 91: 137-168. doi:10.1016/S0065-230X(04)91004-4. PubMed: 15327890.
-
(2004)
Adv Cancer Res
, vol.91
, pp. 137-168
-
-
Marks, P.A.1
Richon, V.M.2
Miller, T.3
Kelly, W.K.4
-
34
-
-
34250171437
-
Histone deacetylase inhibitors: signalling towards p21cip1/waf1
-
doi: 10.1016/j.biocel.2007.03.001
-
Ocker M, Schneider-Stock R, (2007) Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int J Biochem Cell Biol 39: 1367-1374. doi:10.1016/j.biocel.2007.03.001. PubMed: 17412634.
-
(2007)
Int J Biochem Cell Biol
, vol.39
, pp. 1367-1374
-
-
Ocker, M.1
Schneider-Stock, R.2
-
35
-
-
33748451151
-
Anticancer activities of histone deacetylase inhibitors
-
doi: 10.1038/nrd2133
-
Bolden JE, Peart MJ, Johnstone RW, (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784. doi:10.1038/nrd2133. PubMed: 16955068.
-
(2006)
Nat Rev Drug Discov
, vol.5
, pp. 769-784
-
-
Bolden, J.E.1
Peart, M.J.2
Johnstone, R.W.3
|